Novogene America to Exhibit at AACR 2026, Showcasing Advanced Genomics Solutions for Cancer Research
Sacramento, CA — April 2026 — Novogene America, a leading provider of Multi-omics services and solutions, today announced its participation as an exhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 19–22, 2026, in San Diego, California.
At AACR 2026, Novogene America will showcase its comprehensive portfolio of next-generation sequencing (NGS) and multi-omics solutions designed to accelerate cancer discovery, translational research, and precision oncology. These offerings support researchers across the full spectrum of cancer research, from basic science to clinical and translational studies.
Attendees visiting Booth #4720 will have the opportunity to learn more about Novogene America’s service offerings and take advantage of exclusive AACR 2026 event-only promotions, including show-specific pricing, complimentary project consultations, and priority sample intake for qualifying studies.
- Single Cell Sequencing services
- Pre-made Metagenomics Sequencing solutions
- Whole Genome Sequencing (WGS)
- Multiomics services
The AACR Annual Meeting brings together thousands of scientists, clinicians, and industry leaders from around the world to share the latest advances in cancer research. Novogene America’s participation underscores its role as a trusted genomics partner supporting cutting-edge oncology research and innovation.
Researchers and conference attendees are encouraged to visit Novogene America at Booth #4720 during the exhibition April 19–22 to speak with scientific experts, explore recent project highlights, and learn how customized genomics solutions can support their research goals.
